Financial StabilityORKA has a projected cash runway through 2027, supporting its financial stability.
Market OpportunityHalf-life extension could enable ORKA-002 to capture a meaningful slice of the pie, implying a lucrative market opportunity, if ultimately successful.
Product DevelopmentORKA-002 could have best-in-class and rapid onset with two induction doses, potentially providing faster therapeutic benefits compared to competitors.